These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 12972634)

  • 1. The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability.
    Overholtzer M; Rao PH; Favis R; Lu XY; Elowitz MB; Barany F; Ladanyi M; Gorlick R; Levine AJ
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11547-52. PubMed ID: 12972634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular analysis of p53, MDM2 and H-ras genes in low-grade central osteosarcoma.
    Park HR; Jung WW; Bertoni F; Bacchini P; Park JH; Kim YW; Park YK
    Pathol Res Pract; 2004; 200(6):439-45. PubMed ID: 15310147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
    Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
    J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors.
    Yokoyama R; Schneider-Stock R; Radig K; Wex T; Roessner A
    Pathol Res Pract; 1998; 194(9):615-21. PubMed ID: 9793960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Status of the p53, Rb and MDM2 genes in canine osteosarcoma.
    Mendoza S; Konishi T; Dernell WS; Withrow SJ; Miller CW
    Anticancer Res; 1998; 18(6A):4449-53. PubMed ID: 9891508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Alterations of MDM2 and p53 genes in bone tumors].
    Zhou X; Gao L; Zhe X
    Zhonghua Bing Li Xue Za Zhi; 1997 Oct; 26(5):270-2. PubMed ID: 10374333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
    Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
    Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 mutation and absence of mdm2 amplification and Ki-ras mutation in 4-hydroxyamino quinoline 1-oxide induced transplantable osteosarcomas in rats.
    Kido A; Tsujiuchi T; Tsutsumi M; Takahama M; Okajima E; Kobitsu K; Miyauchi Y; Mii Y; Tamai S; Konishi Y
    Cancer Lett; 1997 Jan; 112(1):5-10. PubMed ID: 9029163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
    Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
    Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutations and MDM-2 amplification in renal cell cancers.
    Imai Y; Strohmeyer TG; Fleischhacker M; Slamon DJ; Koeffler HP
    Mod Pathol; 1994 Sep; 7(7):766-70. PubMed ID: 7824511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MDM2 gene amplification in metastatic osteosarcoma.
    Ladanyi M; Cha C; Lewis R; Jhanwar SC; Huvos AG; Healey JH
    Cancer Res; 1993 Jan; 53(1):16-8. PubMed ID: 8416741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Detection of p53 and MDM2 gene expression in osteosarcoma with biotin-labelled in situ].
    Wang X; Wang S; Feng C
    Zhonghua Wai Ke Za Zhi; 1997 Mar; 35(3):178-80. PubMed ID: 10374529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The MDM2 gene amplification database.
    Momand J; Jung D; Wilczynski S; Niland J
    Nucleic Acids Res; 1998 Aug; 26(15):3453-9. PubMed ID: 9671804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
    Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
    Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mdm-2 expression correlates with wild-type p53 status in esophageal adenocarcinoma.
    Soslow RA; Altorki NK; Yang G; Xie D; Yang CS
    Mod Pathol; 1999 Jun; 12(6):580-6. PubMed ID: 10392633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
    Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
    Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
    Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
    J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-resolution array-based comparative genomic hybridization of bladder cancers identifies mouse double minute 4 (MDM4) as an amplification target exclusive of MDM2 and TP53.
    Veerakumarasivam A; Scott HE; Chin SF; Warren A; Wallard MJ; Grimmer D; Ichimura K; Caldas C; Collins VP; Neal DE; Kelly JD
    Clin Cancer Res; 2008 May; 14(9):2527-34. PubMed ID: 18451213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
    Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
    Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.